Damora Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 19, 2025
DMRA$23.70+8.4%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
As of December 31, 2024, the facilities that we lease are the following:
| Location | Primary Use | Approximate Square Footage | Lease Expiration Date | Renewal Option |
|---|---|---|---|---|
| Ole Maaloes Vej 3, DK-2200 Copenhagen N, Denmark | Office space | 350 | November 30, 2029 | None |
We believe that our current facilities are sufficient to meet our current and near-term needs and that, should it be needed, suitable additional space will be available.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.